Pharmaceutical

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

Jan 9, 2024 - 18:00
HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval
HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.
Read the original article

Tags:

Previous Article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Next Article

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis

STAT+: Drug companies and pharmacies reach $17.3 billio...

Jun 10, 2023

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Regeneron and Sanofi’s Dupixent bags fifth drug label i...

Feb 16, 2024

Lilly strikes deal with QurAlis for preclinical ALS candidate

Lilly strikes deal with QurAlis for preclinical ALS can...

Jun 4, 2024